Article 1 to 10 out of 19 concerning Bavarian Nordic A/S
Bavarian Nordic Successfully Completes End of Phase II Meeting for PROSTVAC(12 Mar 2010) Regulatory agencies endorse the overall Phase III plan for PROSTVAC in prostate cancer Bavarian Nordic A/S announced that the company has received Scientific Advice from the European Medicines Agency and concluded an end of Phase II meeting with the US Food and Drug Administration (FDA) for the PROSTVAC(TM) programme. Both agencies ...
Bavarian Nordic updates on Phase I/II studies with breast cancer vaccine(25 Feb 2009) Bavarian Nordic provided updated data from its clinical studies with its breast cancer vaccine, MVA-BN®-HER2, in development as therapy of metastatic breast cancer patients whose tumours over-express HER2. The study met its primary endpoint with ...
Bavarian Nordic reports successful safety data from Phase II study with IMVAMUNE(10 Nov 2008) Bavarian Nordic has completed a clinical safety report from a large Phase II study with IMVAMUNE® in HIV infected subjects that confirms the excellent safety profile of IMVAMUNE®. Within the next few days the safety report of this study will be ...
Bavarian Nordic: Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine(09 Oct 2008) 125 Patient, Prospective Randomized Placebo-Controlled Phase II Study Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer vaccine candidate PROSTVAC(TM) that had been obtained as part of the recently entered partnership with the National Cancer Institute (NCI) in the US.The ...
Bavarian Nordic enters clinical trials with prostate cancer vaccine(06 Jun 2008) Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well ...
Top
